Moreover, tdLN-targeted therapeutic vaccination with exosomes derived from DCs loaded with B16F10 antigens and matured with poly(I:C) shows a beneficial capacity of stimulating B16F10-specific effector CD8+ T cells and recruiting effector T lymphocytes, NK and NK-T cells to the tumor site resulting in smaller tumors and prolonged survival of tumor-bearing mice. The gene discussed is CD8A; the disease is neoplasm.